Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Afamelanotide

FDA-approved product (implant, subcutaneous), marketed as Scenesse.

Registered studies
23
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Afamelanotide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Erythropoietic protoporphyria

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protectives against uv-radiation for systemic use
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Afamelanotide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Afamelanotide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients

    NCT06388642 · start 2024-03-07

    Registered record
    Registry ID
    NCT06388642
    Conditions
    Erythropoietic Protoporphyria
    Interventions
    Afamelanotide 16mg implant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2024-03-07
    Completion
    2025-01-20
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythropoietic Protoporphyria
    InterventionAfamelanotide 16mg implant
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

    NCT06109649 · start 2023-10-11

    Registered record
    Registry ID
    NCT06109649
    Conditions
    Vitiligo
    Interventions
    Afamelanotide and NB-UVB Light; NB-UVB Light
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-10-11
    Completion
    2026-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionAfamelanotide and NB-UVB Light; NB-UVB Light
    PhasePhase 3
    Registry statusActive not recruiting

  • Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

    NCT05854784 · start 2023-03-28

    Registered record
    Registry ID
    NCT05854784
    Conditions
    Variegate Porphyria
    Interventions
    Afamelanotide 16 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-03-28
    Completion
    2023-12-28
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVariegate Porphyria
    InterventionAfamelanotide 16 MG
    PhasePhase 2
    Registry statusCompleted

  • A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

    NCT05210582 · start 2022-10-11

    Registered record
    Registry ID
    NCT05210582
    Conditions
    Vitiligo
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-10-11
    Completion
    2023-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionAfamelanotide
    PhasePhase 2
    Registry statusUnknown

  • A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

    NCT05370235 · start 2022-03-28

    Registered record
    Registry ID
    NCT05370235
    Conditions
    Xeroderma Pigmentosum
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-03-28
    Completion
    2024-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionXeroderma Pigmentosum
    InterventionAfamelanotide
    PhasePhase 2
    Registry statusUnknown

  • DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

    NCT05368857 · start 2022-01-19

    Registered record
    Registry ID
    NCT05368857
    Conditions
    Afamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-19
    Completion
    2023-02-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAfamelanotide Evaluated as Skin DNA Repair Therapy in Healthy Volunteers
    InterventionAfamelanotide
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

    NCT05159752 · start 2021-10-19

    Registered record
    Registry ID
    NCT05159752
    Conditions
    Xeroderma Pigmentosum
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-10-19
    Completion
    2024-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionXeroderma Pigmentosum
    InterventionAfamelanotide
    PhasePhase 2
    Registry statusUnknown

  • A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

    NCT04962503 · start 2021-06-03

    Registered record
    Registry ID
    NCT04962503
    Conditions
    Arterial Ischemic Stroke
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-06-03
    Completion
    2022-02-04
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Ischemic Stroke
    InterventionAfamelanotide
    PhasePhase 2
    Registry statusCompleted

  • Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

    NCT04525157 · start 2014-06-06

    Registered record
    Registry ID
    NCT04525157
    Conditions
    Vitiligo
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-06-06
    Completion
    2016-06-06
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionAfamelanotide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Phase III Confirmatory Study in Erythropoietic Protoporphyria

    NCT01605136 · start 2012-05

    Registered record
    Registry ID
    NCT01605136
    Conditions
    Erythropoietic Protoporphyria
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2013-07
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythropoietic Protoporphyria
    InterventionAfamelanotide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

    NCT01382589 · start 2011-09

    Registered record
    Registry ID
    NCT01382589
    Conditions
    Vitiligo
    Interventions
    Afamelanotide; NB-UVB
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionAfamelanotide; NB-UVB
    PhasePhase 2
    Registry statusCompleted

  • A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

    NCT04578496 · start 2011-07-11

    Registered record
    Registry ID
    NCT04578496
    Conditions
    Erythropoietic Protoporphyria
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-07-11
    Completion
    2014-02-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErythropoietic Protoporphyria
    InterventionAfamelanotide
    PhasePhase 3
    Registry statusCompleted

  • Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

    NCT01430195 · start 2011-06

    Registered record
    Registry ID
    NCT01430195
    Conditions
    Vitiligo
    Interventions
    Afamelanotide; Narrow-Band UVB Light Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2012-11
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitiligo
    InterventionAfamelanotide; Narrow-Band UVB Light Treatment
    PhasePhase 1
    Registry statusCompleted

  • Afamelanotide in Patients Suffering With Acne Vulgaris

    NCT04943159 · start 2010-08-24

    Registered record
    Registry ID
    NCT04943159
    Conditions
    Acne Vulgaris
    Interventions
    Afamelanotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-08-24
    Completion
    2011-03-08
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionAfamelanotide
    PhasePhase 2
    Registry statusCompleted

  • Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

    NCT04704713 · start 2010-05-05

    Registered record
    Registry ID
    NCT04704713
    Conditions
    Polymorphic Light Eruption
    Interventions
    Afamelanotide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-05-05
    Completion
    Not recorded
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolymorphic Light Eruption
    InterventionAfamelanotide; Placebo
    PhasePhase 3
    Registry statusCompleted